Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma Journal Articles

abstract

• Mucinous bronchioloalveolar carcinoma (BAC) can be associated with significant bronchorrhea. A 46-year-old man presented with BAC with 2,000 mL of sputum production on a daily basis, which prevented him from being extubated. As this condition is rare, there are only case reports outlining the therapy for the associated bronchorrhea. We used azithromycin, scopolamine, and inhaled fluticasone with moderate success. The initiation of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, resulted in dramatic improvement in the volume of pulmonary secretions produced. The patient's EGFR mutation status was subsequently found to be negative, which supports the hypothesis that the mechanism of reduction of bronchorrhea is independent of the antiproliferative effect of the drug.

authors

• McIvor, Andrew
• Popat, Nooreen
• Raghavan, Natya
• McIvor, R Andrew

status

• published 

publication date

• February 2012

has subject area

• 1103 Clinical Sciences (FoR)
• Adenocarcinoma, Bronchiolo-Alveolar (MeSH)
• Biopsy (MeSH)
• Gefitinib (MeSH)
• Humans (MeSH)
• Lung Neoplasms (MeSH)
• Male (MeSH)
• Middle Aged (MeSH)
• Protein Kinase Inhibitors (MeSH)
• Quinazolines (MeSH)
• Respiratory System (Science Metrix)
• Sputum (MeSH)
• Tomography, X-Ray Computed (MeSH)

published in

• Chest  Journal

keywords

• Adenocarcinoma, Bronchiolo-Alveolar
• Biopsy
• Gefitinib
• Humans
• Lung Neoplasms
• Male
• Middle Aged
• Protein Kinase Inhibitors
• Quinazolines
• Sputum
• Tomography, X-Ray Computed

Digital Object Identifier (DOI)

• 10.1378/chest.11-0956

PubMed ID

• 22315118

start page

• 513

end page

• 514

volume

• 141

issue

• 2